Latest Conference Articles

April 1st 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

March 31st 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

March 30th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

March 23rd 2022, 7:00pm

SGO Annual Meeting on Women's Cancer

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

March 22nd 2022, 3:00pm

SGO Annual Meeting on Women's Cancer

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

March 22nd 2022, 12:30pm

SGO Annual Meeting on Women's Cancer

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

March 7th 2022, 4:00pm

ASCO Genitourinary Symposium

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

March 1st 2022, 10:00pm

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

February 22nd 2022, 8:00pm

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

February 22nd 2022, 4:41pm

ASCO Genitourinary Symposium

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

February 22nd 2022, 2:08pm

ASCO Genitourinary Symposium

Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.

February 21st 2022, 8:00pm

ASCO Genitourinary Symposium

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

February 21st 2022, 4:00pm

ASCO Genitourinary Symposium

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

February 15th 2022, 8:00pm

Prehab and rehab may help patients with cancer who are receiving CAR-T cell therapy return to health or even better, but there are still challenges.

February 7th 2022, 4:38pm

Treatment with a combination of PD-1 inhibition, minimally invasive chemotherapy and Lenvima improved outcomes for patients with unresectable liver cancer compared to PD-1 inhibition and Lenvima alone.

January 27th 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.

January 26th 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Single-agent adagrasib was associated with encouraging treatment responses in patients with previously treated non-colorectal gastrointestinal tumors and pancreatic ductal adenocarcinoma.

January 26th 2022, 8:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.

January 25th 2022, 4:17pm

ASCO Gastrointestinal Cancers Symposium

A group of patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer experienced responses to treatment with Keytruda plus Mektovi and Avastin.

January 25th 2022, 2:11pm

ASCO Gastrointestinal Cancers Symposium

The use of a ctDNA assay could help determine which patients with colorectal cancer may benefit most from chemotherapy after surgery.

January 24th 2022, 4:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.

January 24th 2022, 2:21pm

ASCO Gastrointestinal Cancers Symposium

The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.

January 23rd 2022, 3:00pm

ASCO Gastrointestinal Cancers Symposium

Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.

January 22nd 2022, 3:00pm

ASCO Gastrointestinal Cancers Symposium

Treating patients with liver cancer initially with Lenvima instead of the standard of care was associated with a survival benefit, according to recent research.

January 21st 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.

January 21st 2022, 2:00pm

ASCO Gastrointestinal Cancers Symposium

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.

January 6th 2022, 2:00pm

SABCS

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

January 5th 2022, 8:15pm

SABCS

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

January 5th 2022, 5:00pm

American Society of Hematology Annual Meeting

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

January 3rd 2022, 10:00pm

SABCS

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.